

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A method for treating users having systemic inflammation by reducing highly sensitive C- reactive protein levels in the body of a user which comprises:

administering in liquid form as a single dose composition, on a daily basis for a period of at least about 2 days, a composition ~~selected from the group~~ consisting essentially of:

- (a) from about 1 to about 20 milligrams of a leukotriene inhibitor,
- (b) from about 150 to about 250 milligrams of an antihistamine,
- (c) from about 110 µcg to about 220 µcg of a corticosteroid and,
- (d) mixtures thereof

to reduce highly sensitive C-reactive protein in the body of the user.

2. **(Canceled)**

3. **(Previously Amended)** The method of claim 1 wherein the selected composition is used in an amount of:

- (a) from about 5 to about 15 milligrams of the leukotriene inhibitor,
- (b) from about 175 to about 200 milligrams of the antihistamine, and
- (c) from about 110 µcg to about 220µcg of the corticosteroid.

4. **(Previously Amended)** The method of claim 1 wherein the leukotriene inhibitor is selected from the group consisting of:

zafirlukast, zileuton and mixtures thereof.

5. **(Previously Amended)** The method of claim 1 wherein the antihistamine is selected from the group consisting of:

cetirizine, fexofenadine, loratadine, and azelastine.

6. **(Previously Amended)** The method of claim 1 wherein the corticosteroid is selected from the group consisting of:

mometasone furoate monohydrate, triamcinalone, acetonide, and budesonide.

7. **(Previously Amended)** The method of claim 1 wherein:

- (a) the leukotriene inhibitor is montelukast sodium,
- (b) the antihistamine is cetirizine, and
- (c) the steroid is fluticasone propionate.

8. **(Previously Amended)** The method of claim 1 wherein the composition comprises:

- (a) the leukotriene inhibitor,
- (b) the antihistamine, and
- (c) the corticosteroid.

9. **(Cancelled)**